Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure

Alexander M. Spence; Mitchel S. Berger; Robert B. Livingston; Francis Ali-Osman; Brian Griffin

doi:10.1007/BF00172671

Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure

Alexander M. Spence, Mitchel S. Berger, Robert B. Livingston, Francis Ali-Osman, Brian Griffin

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.

Original language	English (US)
Pages (from-to)	187-191
Number of pages	5
Journal	Journal of Neuro-Oncology
Volume	12
Issue number	2
DOIs	https://doi.org/10.1007/BF00172671
State	Published - Feb 1992
Externally published	Yes

Keywords

astrocytoma
brain tumors
chemotherapy
cisplatin
glioblastoma
malignant glioma

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1007/BF00172671

Cite this

@article{1660074a027848eb832d28f7b9b2747d,

title = "Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure",

abstract = "Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.",

keywords = "astrocytoma, brain tumors, chemotherapy, cisplatin, glioblastoma, malignant glioma",

author = "Spence, {Alexander M.} and Berger, {Mitchel S.} and Livingston, {Robert B.} and Francis Ali-Osman and Brian Griffin",

year = "1992",

month = feb,

doi = "10.1007/BF00172671",

language = "English (US)",

volume = "12",

pages = "187--191",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure

AU - Spence, Alexander M.

AU - Berger, Mitchel S.

AU - Livingston, Robert B.

AU - Ali-Osman, Francis

AU - Griffin, Brian

PY - 1992/2

Y1 - 1992/2

N2 - Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.

AB - Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.

KW - astrocytoma

KW - brain tumors

KW - chemotherapy

KW - cisplatin

KW - glioblastoma

KW - malignant glioma

UR - http://www.scopus.com/inward/record.url?scp=0026544396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026544396&partnerID=8YFLogxK

U2 - 10.1007/BF00172671

DO - 10.1007/BF00172671

M3 - Article

C2 - 1560266

AN - SCOPUS:0026544396

SN - 0167-594X

VL - 12

SP - 187

EP - 191

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

IS - 2

ER -

Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this